Learn More About Cochleate Technology
Matinas BioPharma’s mission is to transform the way potent medicines are delivered and administered.
MTNB
NYSE American
Matinas BioPharma’s mission is to transform the way potent medicines are delivered and administered.
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications. The Company's proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable.
| Candidate & Indication | Development Stage | ||||
|---|---|---|---|---|---|
| MAT2203 Prevention of IFI in Acute Lymphoblastic Leukemia |
IND Preparation Phase complete
|
Phase 1 Development Phase complete
|
Phase 2 Development Phase in progress
|
Phase 3 Development Phase not started
|
Market Phase not started
|
| MAT2501 Non-Tuberculous Mycobacterium (NTM) Infections |
IND Preparation Phase complete
|
Phase 1 Development Phase in progress
|
Phase 2 Development Phase not started
|
Phase 3 Development Phase not started
|
Market Phase not started
|
Matinas BioPharma Reports 2017 Financial Results
View All Press Releases »